A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma

Summary

The purpose of this study is to determine if the combination of everolimus and imatinib will slow the growth of or cause a reduction in the size of the cancer, and to determine the side effects of the combination in patients with melanoma. Each of the drugs in this combination, if used alone, would not be expected to have an effect against the cancer. However, when used together, there is a possibility that they could work together to damage the cancer cells, or to block the formation or function of the blood vessels that feed the cancer, either of which could result in slowing the growth of or shrinking the cancer. Both drugs work by blocking signals that are sent from outside of a cell to the inside of the cell that direct the cell to make certain substances to keep the cell alive. Cancer cells or blood vessels that feed cancer cells may be more sensitive to drugs that block these signals.

Timeline

Start

2006-02

Primary completion

2006-06

Completion

2006-06

Outcome

Outcome not reported

Stopped: “unexpected level of toxicity”

Drugs

Indications